Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lara Matheson

Urology Houston, TX Medical Doctor

NPI 1114360450 CMS profile 5699104

6560 Fannin St Ste 1440, Houston, TX 77030

Open in the dashboard

General payments

$13,498

411 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$7,407

2 holdings reported · through program year 2025

Through program year 2025, Lara Matheson of Houston, TX is reported in the CMS Open Payments database as having received $13,498 across 411 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $7,407 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,785 82
2024 General $1,683 81
2023 General $1,349 88
2022 General $1,202 60
2021 General $242 11
2020 General $512 29
2019 General $1,726 60
2025 Ownership $3,704 1
2024 Ownership $3,704 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lara Matheson
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Lara Matheson were reported at $6,785. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Lara Matheson Urology median Middle half National median
2019 $1,726 $480 $147–$1,201 $163
2020 $512 $246 $87–$645 $114
2021 $242 $358 $111–$1,000 $132
2022 $1,202 $476 $143–$1,263 $149
2023 $1,349 $560 $168–$1,461 $160
2024 $1,683 $563 $170–$1,464 $164
2025 $6,785 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. HMU Consumables, LLC $5,143 2 payments
  2. Sumitomo Pharma America, Inc. $928 130 payments
  3. Astellas Pharma US Inc $874 31 payments
  4. Medtronic, Inc. $839 16 payments
  5. Pfizer Inc. $595 22 payments
  6. Boston Scientific Corporation $489 13 payments
  7. AbbVie, Inc. $482 20 payments
  8. Janssen Biotech, Inc. $438 19 payments
  9. Axonics Modulation Technologies, Inc. $327 8 payments
  10. Myriad Genetic Laboratories, Inc. $310 13 payments
  11. Other $3,074 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,080 399 payments
  2. Long term medical supply or device loan $5,143 2 payments
  3. Education $257 9 payments
  4. Entertainment $19 1 payment
Products named General payments · program years 2019–2025
  1. Dornier MedTech Ureteroscopy $5,191 3 payments
  2. Dornier MedTech Ureteroscopy $5,191 3 payments
  3. Dornier MedTech Ureteroscopy $5,191 3 payments
  4. Dornier MedTech Ureteroscopy $5,191 3 payments
  5. Dornier MedTech Ureteroscopy $5,191 3 payments
  6. GEMTESA $974 142 payments
  7. XTANDI $952 34 payments
  8. INTERSTIM $679 13 payments
  9. MYRBETRIQ $410 19 payments
  10. ERLEADA $359 16 payments
  11. Other $5,731 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

4,166

Median for Urology: 1,053

Drug cost

$836,756

Median for Urology: $101,464

Branded share of claims

45.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 747 $483,393
Myrbetriq Mirabegron Brand 219 $145,961
Estradiol Generic 553 $39,793
Mirabegron Er Mirabegron Brand 48 $34,692
Fosfomycin Tromethamine Generic 115 $25,603
Premarin Estrogens, Conjugated Brand 48 $20,234
Trospium Chloride Er Trospium Chloride Brand 64 $14,204
Estring Estradiol Brand 26 $13,323
Xyosted Testosterone Enanthate Brand 17 $9,909
Methenamine Hippurate Generic 149 $7,837

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$302,314

Of which drugs: $36,461

Medicare patients

687

Average age 77

Services billed

17,293

531 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 51%
Ischemic heart disease 34%
Osteoporosis 28%
Cancer 27%
Diabetes 22%
Atrial fibrillation 21%
Chronic kidney disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 30 3,900 $19,404
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 21 2,100 $206

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $254
$254 747 —
XTANDI
  • Astellas Pharma US Inc $150
  • PFIZER INC. $9
$159 — —
BOTOX
  • AbbVie, Inc. $81
$81 — 3,900
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $66
$66 — —
XYOSTED
  • Antares Pharma, Inc. $44
$44 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

411 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record